Deferasirox (Exjade, ICL670, CGP72670) is an iron-chelating drug for p.o. treatment of transfusional iron overload in patients with ␤-thalassemia or sickle cell disease. The pharmacokinetics and disposition of deferasirox were investigated in rats. 
Because humans are unable to actively remove iron from the body, a clinically relevant state can occur if toxic levels of iron accumulate. This can occur as a result of repeated blood transfusions (as required in patients with ␤-thalassemia major or sickle cell disease) or because of excessive dietary iron uptake in patients with chronic anemias and hereditary hemochromatosis. Excess iron is deposited in the form of hemosiderin (insoluble "iron cores" of degraded or partially degraded ferritin) primarily in the liver, spleen, several endocrine organs, and myocardium (Gabutti and Piga, 1996; Olivieri, 1999) . If untreated, the gradual accumulation of iron leads to progressive organ dysfunction and ultimately death (Olivieri and Brittenham, 1997) .
Iron-chelating agents are thought to slowly mobilize iron by continuous binding of labile iron present in a "transit pool," which is in equilibrium with the insoluble iron deposits. The iron chelate is then excreted in the urine and/or feces. More than 40 years of clinical experience with deferoxamine (DFO) (Desferal; Novartis, Basel, Switzerland) has clearly established the therapeutic benefit of iron chelation, i.e., forced elimination of iron. For patients with ␤-thalassemia, the introduction of chelation therapy with DFO was life-saving as treatment was shown to reduce iron-related morbidity and to improve quality of life (Brittenham et al., 1994; Gabutti and Piga, 1996) . Similar therapeutic benefits have also been documented for patients with sickle cell disease requiring regular transfusions (Cohen and Martin, 2001 ). However, the short plasma half-life of DFO and its poor p.o. bioavailability necessitates slow s.c. infusions with a pump over 8 to 12 h for 5 to 7 days per week lifelong. This very demanding procedure is associated with poor compliance (Olivieri and Brittenham, 1997) . Indeed, compliance has been shown to be absolutely crucial to obtain the full benefit offered by iron chelation (Gabutti and Piga, 1996) . Deferasirox (Exjade, ICL670 ) is a novel once-daily, p.o. iron chelator designed to treat chronic iron overload in patients with transfu-individually in type IV, standard cages. Apart from bile duct-cannulated rats that received Ringer's solution (Oxoid LTD, Basingstoke, Hampshire, UK) instead of water, the rats had free access to standard food (NAFAG pellets 890; Provimi Kliba AG, Kaiseraugst, Switzerland) and tap water before dosing and during the experimentation period. All the animal studies complied with Swiss animal welfare regulations and followed approved protocols.
Formulation. For intravenous administration of [ 14 C]deferasirox (10 mg/ kg) into the tail vein, the compound was dissolved in polyethylene glycol 400 and diluted with 5% aqueous glucose solution. The resulting ratio of polyethylene glycol 400/glucose solution was 1:4. The final concentration of the dose solution was 5 mg/g. A similar formulation was used for the intravenous administration of the metabolites M1 and M2. For p.o. dosing (by gavage) of [ 14 C]deferasirox 10 or 100 mg/kg, the compound was suspended in 0.5% aqueous Klucel HF (Hercules, Wilmington, DE) , resulting in compound concentrations of 1 or 10 mg/g, respectively. For intravenous administration of [ 14 C]Fe(deferasirox) 2 complex (10 mg/kg), the vehicle was 0.9% sodium chloride solution, resulting in a final concentration of 5 mg/g. Assessment of Absorption, Distribution, Metabolism, and Excretion. The absorption, distribution, metabolism, and excretion (ADME) studies included investigation of the excretion balance, the kinetics in blood and plasma, and the distribution pattern and the metabolism. Samples were collected up to 7 days after intravenous (10 mg/kg) and p.o. (10 and 100 mg/kg) administration of [ 14 C]deferasirox and for up to 4 days (distribution up to 7 days) postdose after intravenous administration of the iron complex [ 14 C]Fe(deferasirox) 2 (10 mg/kg). Three rats from each dosing group were used except for the distribution studies, where one rat per time point was assessed. Radioactivity was determined by liquid scintillation counting (LSC) of biological samples (blood, plasma, urine, bile, feces, organs/tissues, carcass) using a Tri-Carb 2700 TR (PerkinElmer Life and Analytical Sciences, Waltham, MA).
Urine and feces were collected quantitatively (urine on ice) at daily intervals up to 7 days postdose and were stored at Ϫ20°C until further analysis. For the investigation of kinetics in blood and plasma, venous blood (0.2-0.3 ml) was collected sublingually into heparin-containing tubes. During the sample collection, the rats were anesthetized by inhalation of an oxygen/isoflurane mixture (97:3, v/v). Plasma was prepared immediately after blood collection by centrifugation at 2100 rpm for 10 min and stored at Ϫ20°C until further analysis.
The tissue distribution of total radiolabeled components in male rats in the ADME study, in female pregnant rats, lactating rats, and suckling pups was investigated using quantitative whole-body autoradioluminography (QWBAL) (Ullberg, 1977; Miyahara, 1989; Hamaoka, 1990; Johnston et al., 1990; Shigematsu, 1992; Shionoya, 1992) . The sacrificed animals were immediately deep-frozen in a mixture of dry ice and hexane at Ϫ75°C, rapidly shaven, and embedded in a 2% precooled semiliquid gel of sodium carboxymethylcellulose. This rapid freezing procedure was designed to avoid any postmortem diffusion of radioactive material in the body. Sagittal sections of 40-m thickness were obtained at Ϫ20°C in a CM 3600 PLC cryomicrotome (Leica MicroSystems GmbH, Nussloch, Germany) according to the method of Ullberg (1977) . After 48 to 60 h of dehydration at Ϫ23°C, the sections were exposed to Fuji BASIII Imaging plates (Fuji Photo Film Co. Ltd., Tokyo, Japan) for 1 day at room temperature in a lead-shielded box to minimize the background noise signal. The duration of the exposure was chosen to allow detection of approximately 2 dpm/mg, i.e., the concentration corresponding to Ͻ1% of the radioactive dose if the radioactivity was evenly distributed throughout the body. The imaging plates were left for 3 to 4 min at room temperature in the dark and subsequently transferred to a Fuji BAS 2000 TR phosphor imager (Fuji Photo Film Co., Ltd.) to be scanned at 100 m with a 1024 gradation. The tissue concentrations of total radiolabeled components were determined by comparative densitometry using one standard curve for each imaging plate. The results were processed using an MCID/M4 (3.0 Rev. 1.3) image analyzer (Imaging Research, St. Catharines, ON, Canada) and automatically converted into concentrations of total radiolabeled components using a linear calibration curve obtained from a radioactive blood scale processed under the same conditions as the samples (Schweitzer et al., 1987) . For reporting, selected sections were re-exposed for 1 day at room temperature in a lead-shielding box onto SR screens and scanned at 600 dpi (42 m) in a Cyclone PhosphorImager (PerkinElmer Life and Analytical Sciences). The image files were processed using Adobe Photoshop software (Adobe Systems, Mountain View, CA). The limit of detection [(LOD) after p.o. administration, 100 mg/kg: 0.35 g-Eq/g; LOD other studies: 0.007-0.07 g-Eq/g] was defined as the mean of background (n ϭ 10) plus 3 S.D., and the limit of quantification (LOQ) was taken as 3 times the LOD.
Evaluation in Pregnant and Lactating Rats. The placental transfer in pregnant rats was studied 1, 2, 8, and 24 h after p.o. administration of [ 14 C]deferasirox (30 mg/kg) on day 13 and day 17 of gestation by means of LSC (samples from day 13) or QWBAL (samples from day 17). The tissues of the dams, the complete fetuses, placentas, amnion (day 17 only), and amniotic fluid (day 17 only) were analyzed in two dams per time point (1, 2, 8, and 24 h), one animal at day 13 and the other at day 17.
The galactogenic transfer was investigated in lactating rats after p.o. dosing of [
14 C]deferasirox (10 mg/kg). The concentrations of total radiolabeled components and metabolite patterns were analyzed in breast milk and plasma up to 72 h postdose. For sample collection a sparse modus was applied using eight rats (four pups per dam). At each time point plasma and milk were collected from four rats. Samples were taken at 0.5, 4, 24, and 72 h in group 1 and at 2, 8, and 48 h in group 2. To estimate the amount of compound excreted into milk during a collection period, the milk concentration was multiplied by the milk volume produced during that time period (daily milk production 15 ml) (Harkness, 2001) .
The distribution in suckling pups was investigated by QWBAL at 1, 2, 3, 4, 6, 8, 12 , and 24 h after p.o. dosing of [
14 C]deferasirox (10 mg/kg) to the dams. Four dams were dosed, and each dam was kept together with eight pups. At each time point, one pup from each dam was investigated.
Biliary Excretion. Bile was quantitatively collected on ice from the bile duct-cannulated rats (n ϭ 3) up to 72 h after p.o. administration of [ 14 C]deferasirox (10 mg/kg). Radioactivity was determined in bile, urine, and feces. In addition, the metabolite patterns in bile were investigated. For this study, the bile duct of the rats was double-cannulated under anesthesia (isoflurane) according to Rath and Hutchison (1989) . A recovery phase of approximately 48 h was established between surgery and dosing. During this recovery phase, bile was collected. In turn, synthetic bile comprising 25 mmol of sodium taurocholate, 0.3 mmol of 5-cholesten-3␤-ol, and 12.5 mmol of lecithin (3-sn-phosphatidylcholine from egg yolk) per liter of 0.9% sodium chloride solution was continuously infused into the duodenum with a flow rate of 1 ml/h. Furthermore, 0.01 to 0.05 mg/kg buprenorphine (Temgesic; Essex Chemie AG, Lucerne, Switzerland) was administered s.c. before the start of surgery and during the recovery phase for postoperative analgesia.
Enterohepatic Circulation. Two groups of male rats were bile ductcannulated as described above. To group 1 donor rats (n ϭ 3), [ 14 C]deferasirox (12 mg/kg) was administered intravenously (vena femoralis). Bile was collected on ice individually for the time period 0 to 24 h postdose. For the sampling period, synthetic bile was supplemented intraduodenally (1 ml/h). In group 2, one third of the pooled bile collected from group 1 was infused into the duodenum of receiver rats (n ϭ 2) within 24 h at a flow rate of 0.65 ml/h/rat. After this period, synthetic bile was infused into the duodenum (1 ml/h) for the next 24 h. Bile (on ice), urine (on ice), and feces were collected individually and quantitatively in 0 to 24-and 24 to 48-h fractions. Radioactivity was determined in all the fractions and additionally in the gastrointestinal tract, carcass, and cage wash at the end of the study by LSC. The metabolite patterns were investigated in the bile of each rat. To calculate the absorption of deferasirox-related compounds, the sum of radioactivity recovered in bile, urine, and carcass (group 2 rats) was divided by the radioactivity administered into the duodenum. The extent of enterohepatic circulation of deferasiroxrelated compounds after intravenous administration was calculated as follows: percentage of radioactivity excreted with bile (group 1 rats, i.v., 0 -24 h) was multiplied by radioactivity absorbed in percentage (group 2 rats, after infusion into the duodenum), divided by 100.
Iron Excretion. In a supplementary iron excretion study, 50 mg/kg nonradiolabeled deferasirox or its metabolites M1 and M2 was administered intravenously to three bile duct-cannulated rats. The amount of iron excreted through urine and bile (0 -24 h) was analyzed.
Analysis of Deferasirox and Iron Complex. Deferasirox and Fe(deferasirox) 2 were determined in plasma and urine using validated high-performance liquid chromatography (HPLC)/UV (Rouan et al., 2001) or LC/tandem mass spectrometry (MS/MS) methods based on similar HPLC systems. The liquid chromatography (LC)/MS/MS system comprised a Series 200 HPLC setup (PerkinElmer Life and Analytical Sciences) with an API3000 mass spectrometer (Applied Biosystems, Foster City, CA) with the ion source operated in the positive ion mode, the capillary temperature at 270°C, and the spray voltage at 5 kV. Deferasirox and Fe(deferasirox) 2 were measured and quantified separately. In the ADME study with [
14 C]deferasirox using Hanover-Wistar rats, the HPLC/UV method was used for the quantitation of deferasirox and the iron complex in plasma, whereas the LC/MS/MS method was applied in the ADME studies with [
14 C]Fe(deferasirox) 2 complex and [ 14 C]deferasirox in TR Ϫ rats. The lower LOQ in plasma with the HPLC/UV method was 0.67 M (252 ng/ml) for deferasirox and 0.28 M (242 ng/ml) for the iron complex. The lower LOQ in plasma with the HPLC/MS/MS method was 0.67 M (252 ng/ml) for deferasirox and 0.31 M (268 ng/ml) for the iron complex.
Metabolite Profiling. Sample preparation. Before HPLC analysis, plasma aliquots from three animals were pooled per time point, diluted with 2 or 3 volumes of HPLC start solvent, and centrifuged. Urine aliquots from two to four rats were pooled over 0 to 48 h postdose, diluted 5 to 10-fold with HPLC start solvent, and centrifuged. Aliquots of feces homogenates from three rats were pooled over 0 to 48 h and extracted with 6 volumes of acetonitrile during 30 min over a shaker. The contents were centrifuged, and the supernatant was concentrated in vacuo. The extraction recovery of radioactivity was 86 to 95%. Bile aliquots from two rats were pooled over 0 to 48 h postdose and diluted with 10 volumes of HPLC start solvent.
HPLC methods for metabolite profiling and radioactivity detection. Metabolites contained in processed sample aliquots were separated using a Jasco micro-HPLC setup (Jasco, Tokyo, Japan). Chromatography was run on LiChrospher 100-5 RP18 ec (particle size 5 m, pore size 100 Å end-capped, 250 ϫ 2 mm i.d., Machery-Nagel, Düren, Germany) with guard column (4 ϫ 2 mm i.d., same adsorbent) at 25°C. A solvent gradient was formed from 25 mM aqueous ammonium formate with 2.5 mM EDTA, pH 5.5/acetonitrile (99:1 v/v) (A) and acetonitrile (B), at a flow rate of 200 l/min with the following characteristics: run time (min)/%A: 0:95, 10:90, 60:55, 65:5, and 70:5. Aliquot volumes of 50 to 200 l were injected. A Jasco ultraviolet diode array detector MD-910 at 235-or 260-nm wavelength in combination with an on-line, flow-through 500 TR series radioactivity detector (PerkinElmer Life and Analytical Sciences) with 100 l of admixing cell was used. LSC mixture Flo-Scint A (PerkinElmer Life and Analytical Sciences) was added at a flow rate of 0.6 ml/min. Recovery from HPLC was close to 100% for plasma, urine, bile, and feces extract. For micropreparative purposes, 4-mm i.d. columns with Nucleosil 100-5, C18 HD (Machery-Nagel), and a flow-through radiomonitor 506 C-1 (Berthold, Wildbad, Germany) equipped with a YG 150 solid scintillator cell or with liquid scintillator admixture were used.
The LC/MS system comprised an Agilent 1100 HPLC setup (Agilent Technologies, Waldbronn, Germany) with a Finnigan Deca XP ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) and a radioactivity detector, 500 TR series (PerkinElmer Life and Analytical Sciences). The chromatography system described above for metabolite profiling was used except that the mobile phase contained no EDTA. MS was operated both in the positive and negative ion mode with the capillary temperature at 270°C and the spray voltage at 4.8 and Ϫ4.0 kV (for electrospray ionization in the positive and negative mode, respectively). The auxiliary gas and sheath gas flow rate were at 0 and 31 arbitrary units, respectively. In-source fragmentation was performed at 20, 45, and 70 V. Xcalibur software, version 1.3 (Thermo Fisher Scientific) was used for instrument control, data acquisition, and data processing. Metabolites were identified based on their observed mass and fragments in (MS/)MS experiments. The isotope pattern resulting from the presence of 14 C atoms facilitated the interpretation of signals from drug-related metabolites. In addition, reference substances of the hydroxylated metabolites M1, M2, M4, and M5 were synthesized. The synthesized metabolites were compared with those isolated from the biological samples to confirm their structure identification.
Alternatively, a quadrupole time-of-flight MS (Waters, Milford, MA) was used with electrospray ionization in negative ion mode and with the following settings: capillary temperature 100°C; desolvation gas temperature 150°C; cone voltage 30, 60, or 90 V; and collision energy 22 to 30 V. HPLC was run with a solvent gradient formed from water and acetonitrile containing 0.1% trifluoroacetic acid (v/v) .
NMR spectroscopy. Metabolite M3 was isolated from bile samples. Serial HPLC chromatography of bile aliquots with the same HPLC column as dmd.aspetjournals.org described above for metabolite profiling but with a 4-mm i.d. bore was used for collection of separated fractions. This was followed by a second HPLC purification step and provided metabolite M3. Feces samples were extracted with acetonitrile, and the extracts were subject to serial HPLC chromatography, yielding metabolites M1, M2, and M4 in amounts of 200 to 280 g and in high purity suitable for NMR spectroscopy. NMR spectroscopy of deferasirox and of purified metabolites was performed on a Bruker DRX-500 NMR spectrometer (Bruker Biospin AG, Fällanden, Switzerland) with a 5-mm broadband inverse probe with z-gradient. Unambiguous assignment of all the 1 H NMR and 13 C NMR signals of deferasirox was a key prerequisite to metabolite structure elucidation. Typically, solutions of 5 to 30 mg of deferasirox in 0.7 ml of dimethyl sulfoxide (DMSO)-d 6 were used in 1 H NMR, 13 C NMR, 1 H, 1 H correlation spectroscopy (COSY), 1 H, 13 C COSY, and long-range 1 H, 13 C COSY measurements in 2.5-mm tubes in DMSO-d 6 at 27°C. Based on their MS and 1 H NMR spectra and compared with deferasirox, the chemical structures of metabolites M1, M2, M3, and M4 were identified, particularly with respect to the exact position of either the OH-or glucuronic acid substituents.
Metabolite profiles in bile after conjugate cleavage. To investigate the presence of an acylglucuronide, bile samples (400 l) were treated with 1.6 ml of buffer of pH 10 (30 mM disodium tetraborate ϩ 42 mM sodium hydroxide) for 20 h at 37°C. Then, an aliquot was acidified with formic acid to pH 3 and analyzed by HPLC as described in the method for metabolite profiling. In parallel samples, the pH was adjusted with 1.6 ml of buffer of pH 5.1 (0.82 M acetic acid, 1.80 M sodium acetate), and 40 l of a ␤-glucuronidase/arylsulfatase mixture was added. Incubation was run at 37°C for 20 h. After incubation, the sample was acidified with formic acid to pH 3 and analyzed by HPLC.
Analysis of Iron. Iron was analyzed in urine and bile using a two-step analytical procedure. In the first step, the sample was digested, i.e., the sample matrix together with the iron complex(es) were completely degraded (mineralized) and dissolved by a wet-chemical oxidation process with nitric acid as oxidant at high temperatures in a microwave-heated high-pressure autoclave. In the second step, iron ions were measured by inductively coupled plasma optical emission spectrometry using a PerkinElmer Optima 3000XL ICP-OES system. This method is a validated analytical procedure applicable to the determination of iron in various biological matrixes, such as urine, serum, and blood. In urine, typically iron levels in the range between 100 g/l and 6 mg/l can be quantitatively determined. In bile, a concentration range from 0.5 to 100 mg/l can be determined directly from the mineralized solutions.
Pharmacokinetic Analysis. The concentrations of total radiolabeled components in plasma and tissues are given in g-Eq/ml or g-Eq/g based on the respective parent compound [deferasirox or Fe(deferasirox) 2 ]. The converting factors into mol/ml or mol/g were 373.4 for deferasirox and 865.5 for Fe(deferasirox) 2 . Area under the plasma concentration-time curve (AUC) and area under the first-moment curve of the plasma concentration-time curve (AUMC) were calculated by the linear trapezoidal rule. The following parameters were calculated using the equations below:
CL ͑clearance͒ ϭ Dose iv րAUC MRT ͑mean residence time͒ ϭ AUMCրAUC V ss ͑volume of distribution at steady state͒ ϭ CL ⅐ MRT bioavailability of deferasirox ͑in %͒:
The p.o. absorption was defined as the sum of the urinary and biliary excretion of total radiolabeled components after administering 10 mg/kg [ 14 C]deferasirox to bile duct-cannulated rats. The in vivo blood distribution of total radiolabeled components was calculated by comparing the concentrations of total radiolabeled components in blood (C b ) with that in plasma (C p ) after intravenous and p.o. administration, according to the formula {100
Results
Pharmacokinetics. The pharmacokinetic parameters and the concentration-time curves of total radiolabeled components, deferasirox, and its complex, Fe(deferasirox) 2 , are summarized in Table 1 and shown in Fig. 2 . After intravenous administration of [ 14 C]deferasirox (10 mg/kg), the concentrations of total radiolabeled components in plasma declined rapidly: 20 and 3% of the initial concentrations of total radiolabeled components (C 5 min in plasma 23 g-Eq/ml) were observed at 2 and 8 h postdosing, respectively. The lowest detectable concentration of total radiolabeled components was analyzed in the 48-h plasma sample (0.019 g-Eq/ml). The concentrations of total radiolabeled components basically represented the combined concentrations of unchanged deferasirox and Fe(deferasirox) 2 in plasma, which was in line with the low amounts of metabolites seen in plasma in Hanover-Wistar rats. Considering the time range of 5 min to 4 h, a half-life of 0.7 h was estimated for deferasirox. A terminal elimination phase with a longer half-life seems to follow but could not be characterized. The plasma clearance of 6.2 ml/min/kg, which corresponds to a blood clearance of 9.9 ml/min/kg, and the volume of distribution of 0.46 l/kg were low and moderate, respectively. The blood clearance represented 18% of the hepatic blood flow in rats (13.8 ml/min) (Davies and Morris, 1993) , which classifies deferasirox as a drug with a low to moderate extraction ratio.
After p.o. administration of [ 14 C]deferasirox (10 mg/kg) to Hanover-Wistar rats, C max of total radiolabeled components was observed in plasma at 0.5 h (3.18 g-Eq/ml). Thereafter, the 14 C levels declined rapidly to 0.022 g-Eq/ml at 24 h. With the multiex- 
DF, deferasirox; DF complex, Fe(deferasirox) 2 ; N.C., not calculated. a To convert concentration data from mass units (g/ml for defined compounds, g-Eq/ml for 14 C concentrations) to molar units (mol/ml), divide by 373.4 (deferasirox) or 865.5 ͓Fe(deferasirox) 2 ͔.
b For deferasirox after intravenous dosing, a time range of 5 min to 4 h and for Fe(deferasirox) 2 of 5 min to 2 h was considered. c For the initial elimination phase for deferasirox after p.o. dosing, the time range from 1 to 2 h was considered. This half-life is only a descriptive estimate because of the low number of sampling time points.
ponential elimination and the limited number of pharmacokinetic time points (see Fig. 2b ), it was not feasible to determine the elimination half-lives accurately after p.o. dosing. For the initial elimination phase, a half-life of approximately 0.5 h can be estimated. After p.o. administration of [ 14 C]deferasirox (100 mg/kg), the course of the kinetics in plasma was different from that observed after the 10 mg/kg dose. A plateau of high concentrations of total radiolabeled components (50.8 -56.4 g-Eq/ml) was observed between 1 and 8 h. Thereafter, the concentrations of total radiolabeled components declined rapidly to 0.98 g-Eq/ml at 24 h. The bioavailability of deferasirox after p.o. dosing of 10 mg/kg was moderate (26%). After p.o. administration of the 100 mg/kg dose, the exposure to deferasirox was overproportional; the AUC was 106-fold higher after the 100 mg/kg dose than after the 10 mg/kg dose. Therefore, the bioavailability could not be determined adequately for the high dose.
The combined concentrations of unchanged deferasirox and Fe(deferasirox) 2 in plasma of Hanover-Wistar after p.o. dosing and intravenous administration were similar to the concentrations of total radiolabeled components. Independent of the route of administration, the deferasirox/Fe(deferasirox) 2 ratio in plasma declined with time from 56 to 3.8 (10 mg/kg i.v., 0.083-4 h), 14 to 1.7 (10 mg/kg p.o., 0.5-8 h), and 79 to 23 (100 mg/kg p.o., 0.5-8 h). Irrespective of the administration route or dose, the radioactivity in blood, which represents predominantly deferasirox, was bound to erythrocytes to an extent of approximately 25%.
Based on the combined excretion data of bile and urine from rats dosed with 10 mg/kg [ 14 C]deferasirox, p.o. absorption was 75%. Comparison of the renal radioactivity excretion after i.v. administration of a 10 mg/kg dose (7.2%), as well as of a p.o. 10 mg/kg dose (7.1%) versus that after a p.o. 100 mg/kg dose (10.6%), suggests that Only the concentrations of total radiolabeled components in Hanover-Wistar rats were analyzed in individual animals. Deferasirox and Fe(deferasirox) 2 and concentrations of total radiolabeled components in TR Ϫ rats were analyzed in pools of three rats.
DISPOSITION OF DEFERASIROX IN RATS
at ASPET Journals on June 22, 2017 dmd.aspetjournals.org the 100 mg/kg dose was absorbed to a similar extent as the low doses. Note that no experiment in bile duct-cannulated rats was performed with the 100 mg/kg dose. After intravenous administration of [ 14 C]Fe(deferasirox) 2 (10 mg/ kg), the concentrations of total radiolabeled components in plasma declined more rapidly than after administration of deferasirox: 12, 0.8, and 0.02% of the initial 14 C concentrations (C 5 min in plasma 91.7 g-Eq/ml) were observed at 1, 8, and 96 h, respectively. Within the observation period (up to 2 h postdose), the concentration of total radiolabeled components in plasma consisted mainly of the deferasirox-iron complex and deferasirox. Considering the time range of 5 min to 2 h, a half-life of approximately 0.4 h was estimated for Fe(deferasirox) 2 . The Fe(deferasirox) 2 /deferasirox ratio changed in plasma dramatically between 5 min (25) and 2 h (1.4) postdose. The concentrations of the complex decreased markedly between these time points (90.0 to 1.90 g/ml), whereas the concentrations of deferasirox were similar between 5 min and 1 h (approximately 1.5 g/ml) and declined between 1 and 4 h to roughly 8-fold lower levels.
Tissue Distribution. The tissue distribution pattern was typical for an organic, acidic compound. Irrespective of the dose, the radioactivity was moderately distributed throughout the body as indicated by concentrations of total radiolabeled components in most organs and tissues similar or lower to those in blood, except for organs and tissues involved in excretion processes.
In the albino animals, the maximal concentrations of total radiolabeled components in individual tissues after 10 and 100 mg/kg p.o. doses of [
14 C]deferasirox were observed at 4 h postdose. At this time point, the highest concentrations of total radiolabeled components were found in the kidney cortex, liver, and intestine (approximately 3-4.5 and 235-280 g-Eq/g after administration of the 10 and 100 mg/kg doses, respectively). The concentrations of total radiolabeled components in the other tissues were close to or below LOQ. After p.o. administration of both doses, the distribution patterns were similar at 4 and 8 h postdose, with individual tissue concentrations only slightly lower after 8 h. After p.o. administration of the 100 mg/kg dose, the highest AUC 0 -168 h was found in the brown fat, liver, kidney, and skin, which were approximately 7.1 to 2.5-fold that of blood. A whole-body autoradiogram of an albino rat is shown in Fig.  3a . In the pigmented rats, the distribution pattern was similar to that in albino rats, and no uptake of radioactivity into the melanincontaining structures was observed.
At 5 min after intravenous dosing of [ 14 C]deferasirox (1 mg/kg, pigmented rat), the highest levels of total radiolabeled components were observed in the liver and kidney cortex (88.9 and 73.6 g-Eq/g) followed by the heart, lung, adrenal, salivary gland, and blood (27 to 18 g-Eq/g) (Fig. 3b) . Total radiolabeled components were not quantifiable at 168 h after intravenous administration in all investigated tissues.
After intravenous administration of [ 14 C]Fe(deferasirox) 2 (10 mg/ kg), the tissue distribution of total radioactivity was primarily intravascular, which is in line with the low volume of distribution (Table  1) . The highest exposure values of total radiolabeled components (estimated for up to 8 h postdose) were observed in bile, liver, and kidney substructures (cortex, medulla, pelvis), which were between 2 and 7 times greater than in blood (32 g-Eq/ml ⅐ h). At 168 h, residual radioactive traces were detected in the kidney cortex, bone marrow, spleen, liver, and lung, amounting to 0.4% of the total dose. Galactogenic Transfer. Approximately 3.3% of the radioactivity administered was transferred to the breast milk of lactating rats within 72 h after the p.o. dose of [
14 C]deferasirox (10 mg/kg). The transfer of radioactivity into the milk was rapid, and the highest concentration of total radiolabeled components in the milk was observed at 2 h postdose (19.8 g-Eq/ml). The milk/plasma ratios of radioactivity were highest in the time range 2 to 24 h postdose (between 10 and 24). The apparent terminal half-life in milk was approximately 5 h. In milk, approximately 80% of the recovered radioactivity corresponded to the parent compound. In female lactating rats, as investigated in the tissue distribution study by QWBAL, concentrations of total radiolabeled components in the mammary glands (0.078 g-Eq/g) at 24 h after p.o. dosing (10 mg/kg) were similar to those in the liver and kidney medulla (Fig. 3c ) and approximately 3 times higher than in blood.
Absorption and Distribution in Suckling Pups. The suckling pups were exposed to deferasirox and/or its metabolites for at least 24 h after p.o. administration of [
14 C]deferasirox (10 mg/kg) to the dams. Concentrations of total radiolabeled components above LOQ (0.022 g-Eq/g) were detected in the kidney cortex, liver, lung, muscle, esophagus, skin, and stomach content of the pups. C max in pups was observed at 8 h postdose in the liver and kidney cortex (approximately 0.56 g-Eq/ml), which is approximately 8 times lower than in the respective tissues of male rats after p.o. administration at the same dose level. A whole-body autoradiogram of a suckling pup is shown in Fig. 3d .
Placental Transfer. The placental transfer of deferasirox-related components into the fetuses after a 30 mg/kg p.o. dose of [ 14 C]deferasirox was minimal, the concentrations of total radiolabeled components being at least 12-fold lower than in the blood for the respec- Ϫ rats (e-h). The feces were collected from rats that were not bile duct-cannulated and therefore show all the metabolites eliminated through bile after conjugate cleavage in the gut; a and e, 2-h plasma; b and f, 0-to 48-h bile; c and g, 0-to 48-h feces; d and h, 0-to 48-h urine.
at ASPET Journals on June 22, 2017 dmd.aspetjournals.org tive dams and up to 36-fold lower than those in the placenta. The radioactivity in the fetuses represented Ͻ0.005% of the administered dose and seemed to be distributed evenly. No radioactivity was detected in the amnion and amniotic fluid at all the time points on day 17. A whole-body autoradiogram of a pregnant rat on day 17 is shown in Fig. 3e .
Assessment of Metabolites. In radiochromatograms of plasma after intravenous dosing, the predominant component was unchanged [ 14 C]deferasirox, representing 81% of the AUC 0 -8 h of plasma radioactivity (Fig. 4a) . Under conditions of sample preparation and chromatography for metabolite patterns, the iron complex dissociated. Therefore, the Fe(deferasirox) 2 complex could not be measured by this analytical method, and the [ 14 C]deferasirox peak included drug substance that had been present in the form of the complex. Metabolite M3 represented 1% of the radioactivity AUC 0 -8 h .
The major route of elimination was through bile (69.3% of the dose within 72 h after p.o. dosing) (Table 3; Fig. 4b ). Similar metabolite patterns were observed in bile after p.o. and intravenous dosing. The acylglucuronide (metabolite M3) was predominant (Fig. 5) . After 10 mg/kg p.o. dosing, M3 accounted for 26.6% and parent drug for 7.7% of the dose. Furthermore, approximately 10 metabolite peaks were detected, and each accounted for 0.1 to 7.4% of the dose (see Table 2 ). Treatment of bile with ␤-glucuronidase/arylsulfatase caused the disappearance of metabolites eluting in the retention time range between 28 and 40 min, with simultaneous formation primarily of the hydroxy metabolites M1, M2, and deferasirox. This indicates that these metabolites were largely glucuronide and/or sulfate conjugates. Therefore, the bulk of the absorbed dose fraction was eliminated in the form of phase II metabolites by hepatobiliary transport.
Under the analytical conditions, the iron complex could not be measured in the bile. Therefore, no conclusions could be drawn regarding the biliary excretion of the Fe(deferasirox) 2 complex. However, in a separate study in rats with 50 mg/kg deferasirox, 356 and 39 g of iron was excreted through bile and urine, respectively, within 24 h postdosing. This finding was indirect evidence that the Fe(deferasirox) 2 complex was excreted through bile and urine.
The fecal excretion of radioactivity after p.o. administration of 10 mg/kg [ 14 C]deferasirox to the bile duct-cannulated rats (0 -72 h) amounted to 21.5% of the dose, representing nonabsorbed parent drug. The fecal excretion of radioactivity after intravenous administration of [ 14 C]deferasirox to Hanover-Wistar rats (0 -168 h) amounted to approximately 89.0% of the dose (Table 3) . [ 14 C]Deferasirox was the major compound in feces extracts both after intravenous and p.o. dosing (see Table 2 and Fig. 4c ). Furthermore, hydroxylated metabolites M1, M2, M4, and M5 were detected. The total content of the metabolites represented 23% of the administered p.o. dose. The metabolite pattern in the feces differed from that in the bile. This is explained by microbial enzymatic degradation of the biliary metabolites (conjugates) in the gut, which leads to liberation of deferasirox and the main phase I metabolites.
A typical metabolite pattern in urine after intravenous dosing is shown in Fig. 4d . After p.o. dosing, the sum of characterized conjugated metabolites (M3, M6, M7, M8, and M1) amounted to 3.0% of the administered dose. The most prominent metabolite M4 amounted to 1.9% of the dose (Table 2) .
In some plasma chromatograms, a front peak (P3) was observed. To investigate the nature of P3, this peak was collected during HPLC analysis, evaporated to dryness, redissolved in buffer, and reinjected into the same HPLC system. The resulting pattern showed a main peak at the retention time of [ 14 C]deferasirox. Therefore, P3 is considered to represent mainly protein-bound deferasirox. Metabolite P16, which was observed in plasma and urine, could not be identified.
Identification of Chemical Structures of Metabolites.
Mass spectrometric data. The mass spectrometric data for deferasirox and its metabolites, obtained by LC/MS, are shown in Table 4 . The primary metabolites M1, M2, M4, and M5 were found to contain an additional hydroxy group (Fig. 5) . The benzoic acid part (Ϫ44, Ϫ120 atomic mass units) was unchanged for M1 and M4; thus, the hydroxy group was attached to one of the phenol rings of deferasirox. In several metabolites, the presence of a glucuronic acid and/or sulfate moiety was clearly indicated by mass increments of 192/176 and 96 atomic mass units, respectively, compared with deferasirox, and by the corresponding fragmentation (Ϫ176, Ϫ80). The main metabolite M3 showed a fragmentation sequence that indicated the presence of a FIG. 5 . Chemical structures of the major metabolites of deferasirox detected in plasma, urine, bile, and feces of rats.
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at ASPET Journals on June 22, 2017 dmd.aspetjournals.org glucuronic acid moiety (Ϫ176) attached to the carboxylate group (Ϫ44) of the benzoic acid part (Ϫ120). This structure was consistent with the chemical instability of M3 at alkaline pH, under which conditions deferasirox was liberated. Instability and cleavage at elevated pH is a common property of acyl glucuronides (Shipkova et al., 2003) . In addition, at neutral pH, rearrangement can occur in this type of compound by migration of the acyl substituent from the 1-O position in the glucuronic acid to 2-O, 3-O, and 4-O positions. In LC/MS analyses, rearrangement product(s) with a molecular ion peak of 550 in the positive ion mode, which is the same as for M3, were detected as a slightly shifted peak M3Ј. M3 itself was stable in plasma, urine, and bile samples at 0°C and Ϫ20°C in the dark. However, a decrease in the peak area of M3 with an accompanying increase of the peak area of M3Ј was observed with bile samples that were left at room temperature overnight. The same molecular weights of M3 and M3Ј, the small difference in HPLC retention time, and the formation of M3Ј with simultaneous disappearance of M3 at room temperature suggest that the rearrangements product(s) are caused by acyl migration. It can be noted here that reanalysis of bile samples after storage at Ϫ20°C for more than 1 year reproduced the same metabolite pattern as depicted in Fig. 4b , which showed stability and very slow conversion to acyl-migrated products.
NMR of deferasirox. The 1 H NMR spectrum of deferasirox in DMSO-d 6 is shown in Fig. 6a (signal range) and in Fig. 6b (only  aromatic region) . A systematic numbering of the carbon atoms from C-1 to C-24 was used for NMR as shown in Fig. 7 . This numbering differed from the common chemical numbering used for deferasirox substructures (see Fig. 8 ) but was introduced to unambiguously denote each C-atom position. The NMR data of deferasirox, including 13 C shifts, 1 H shifts, multiplicities, and homonuclear and heteronuclear Table 6 . A key requirement was the unambiguous assignment of the signal sets of the two phenolic ring systems (C-12-17 versus C-18 -23) attached to C-3 and C-5 of the triazole ring, respectively. According to Begtrup et al. (1988) and Schleucher et al. (1994) , the 13 C NMR shifts of the C-3 atom in N-1-substituted 1,2,4-triazoles are shifted to low field compared with the shift of the C-5 atom. Thus, in a heteronuclear multiple bond correlation (HMBC) experiment, the H-17 signal at 8.04 ppm (see Table 5 and Fig. 6 ) was shown to correlate to the 13 C signal at 159.9 ppm (C-3 of triazole), and H-23 at 7.54 ppm correlated to the 13 C signal at 152.0 ppm (C-5 of triazole). Figure 7 shows the important COSY, rotating frame nuclear Overhauser enhancement spectroscopy, and HMBC correlations in deferasirox used for the complete 1 H and 13 C signal assignment.
NMR of hydroxylated metabolites. The 1 H NMR spectra of the purified metabolites M1, M2, and M4 were collected as for deferasirox. The spectral data are compiled in Table 6 . The spectra of these three metabolites showed one additional exchangeable proton compared with deferasirox, verifying the existence of a third OH group indicated by MS. Correspondingly, one 1 H signal for the site (C atom) of OH substitution was missing. Specific 1 H NMR signals showing characteristic shifts compared with deferasirox are indicated in Table  6 in bold font. For M1 and M2, the chemical shifts of H-20 through -23 and H-7/11 and H-8/10 were comparable with deferasirox. For M4, the shifts of H-14 through -17 and H-7/11 and H-8/10 were comparable. In contrast, at the ring system where the OH substituents were located, high-field shifts of the 1 H signals were observed, and the multiplicities of the 1 H signals in that ring were reduced. An OH group in an aromatic six-member ring causes a strong high-field shift in ortho and para positions but not in the meta position. M4 showed characteristic signal shifts analogous to those of M1, although in the phenol ring at triazole-C-5. Furthermore, meta coupling of "isolated" 1 H signals (H-17 and H-23, respectively) ruled out other substitution patterns in M1 and M4. A different substitution pattern was seen in M2, with a characteristic triplet for H-16. With these considerations, it was possible to distinguish the noncompatible regioisomers and identify the correct substituent positions. Thus, the sites of OH substitution in the metabolites could be assigned unambiguously. Furthermore, the chemical structures of M1, M2, and M4 were confirmed by synthesis of reference materials that showed identical NMR and MS spectra. The structures are indicated in Fig. 8 .
NMR of metabolite M3. The 1 H NMR spectrum of the glucuronide M3 was evaluated as above. The chemical shifts for H-20 through -23 and H-14 through -17 were essentially unchanged compared with the 1 H signals of deferasirox. On the other hand, the 1 H signals of H-8/10 shifted to a low field, showing presence of the glucuronide at the carboxylate group of deferasirox. The 1 H shifts are 5.62 and 3.85, denoted as H-1Ј and H-5Ј in Table 6 , respectively, and could be clearly assigned to glucuronic acid proton signals. No evidence for acyl migration was observed.
Characterization of minor metabolites. LC/MS revealed that the minor metabolite, M6, was a direct glucuronic acid conjugate of deferasirox. It was shown to be identical to the M6 metabolite detected in urine from a mouse ADME study (results not shown here). The latter metabolite was analyzed using an LC/NMR approach similar to that described here.
1 H NMR signals of M6 were largely unchanged compared with deferasirox except for H-14 and H-16, which showed a down-field shift of approximately 0.4 and 0.2 ppm, respectively. Therefore, M6 was identified as the 2-O-glucuronic acid conjugate of deferasirox. The minor metabolite, M5, was shown by LC/MS to be a hydroxylated metabolite different from M1, M2, and M4. Although a sufficient amount for NMR could not be purified, it proved to be identical to a synthetic reference compound carrying the hydroxyl group in position "C-3" by comparison of HPLC retention times and MS data. In urine, the minor metabolites M7 through M11 were found to be glucuronic acid or sulfate conjugates of hydroxy- Fig. 8 The results for M1, M2, M4, and M5 were confirmed by analysis of synthetic reference compounds. Table 3 . After intravenous (10 mg/kg) and p.o. (10 or 100 mg/kg) doses of [ 14 C]deferasirox, excretion in urine and feces was complete (mean: 101% of the dose, n ϭ 9, CV 4%) within 7 days postdose. Excretion in urine was minor (6 -11%). After a p.o. administration of 10 mg/kg to bile duct-cannulated rats, 6.3, 69.3, and 21.5% of the dose 
MS data of deferasirox and its metabolites, and the chemical structure of deferasirox with common numbering of substructures as in
M ϩ H Ϫ glucuronic acid) 564 344 (M-H Ϫ glucuronic acid) 5-O-glucuronide M7 469 470 390 (M ϩ H Ϫ sulfate) 468 388 (M-H Ϫ sulfate) 344 (M-H Ϫ sulfate Ϫ CO 2 ) 268 (M-H Ϫ sulfate Ϫ benzoic acid) 5-O-sulfate M8 469 470 390 (M ϩ H Ϫ sulfate) 468 388 (M-H Ϫ sulfate) 344 (M-H Ϫ sulfate Ϫ CO 2 ) 268 (M-H Ϫ sulfate Ϫ benzoic acid) 3-O-sulfate M11 565 566 390 (M ϩ H Ϫ glucuronic acid) 564 388 (M-H Ϫ glucuronic acid) 344 (M-H Ϫ glucuronic acid Ϫ CO 2 ) Ϫ 268 (M-H Ϫ glucuronic acid Ϫ benzoic acid) 3Ј-O-glucuronide M6 549 550 374 (M ϩ H Ϫ glucuronic acid) 548 372 (M-H Ϫ glucuronic acid) 328 (M-H Ϫ glucuronic acid Ϫ CO 2 ) 2-O-glucuronide M13 453 454 374 (M ϩ H Ϫ sulfate) 452 372 (M-H Ϫ sulfate) 328 (M-H Ϫ sulfate Ϫ CO 2 ) 252 (M-H Ϫ sulfate Ϫ benzoic acid) 2-or 2Ј-O-sulfate M12 629 630 550 (M ϩ H Ϫ sulfate) 374 (M ϩ H Ϫ glucuronic acid Ϫ sulfate) 628 548 (M-H Ϫ sulfate) 372 (M-H Ϫ glucuronic acid Ϫ sulfate) 328 (M-H Ϫ glucuronic acid Ϫ sulfate Ϫ CO 2 )
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at ASPET Journals on June 22, 2017 dmd.aspetjournals.org was recovered in urine, bile, and feces, respectively. After intravenous administration of 10 mg/kg [ 14 C]Fe(deferasirox) 2 , the recovery of radioactivity in the excreta was very similar to that observed for deferasirox.
Enterohepatic Circulation. After intravenous administration of 12 mg/kg [ 14 C]deferasirox to double bile duct-cannulated rats (group 1, donor rats), the fraction of radioactivity excreted via bile was 82.6% (rat 1) and 73.7% (rat 2) within the 24-h sampling interval and 61.5% (rat 3) within the 6-h sampling interval. In the bile pool of the three rats, the pattern of metabolites was similar to that shown in Fig. 4b . After the continuous intraduodenal infusion of the donor bile to the two receiver rats (group 2 rats), within 24 h postdose radioactivity was recovered in the bile (28.7%), urine (1.6%), feces (26.4%), gastrointestinal tract (20.9%), carcass (8.7%), and in cage wash (7.6%; mean values each). Accordingly, absorption of deferasirox-related compounds from the duodenum of the receiver rats amounted to 39%. The extent of enterohepatic circulation FIG. 7. Important COSY, rotating frame nuclear Overhauser enhancement spectroscopy, and HMBC correlations in deferasirox. The numbering of C atoms from 1 to 24 differs from the common chemical numbering (see Fig. 8 ) but was used for unambiguous denotation of C atoms in NMR.
was calculated to be 30.5% of the intravenously administered dose based on the biliary excretion of donor rats 1 and 2. Because the proportion of unchanged [ 14 C]deferasirox in the infused bile was only 12.5%, it was concluded that metabolites must have been reabsorbed as well. Conjugates of deferasirox in the bile of the donor rats may have been cleaved in the gut, and liberated deferasirox may then have been reabsorbed. The 
H NMR data of deferasirox and its metabolites
Carbon atoms were numbered systematically from C-1 to C-24, as shown in Fig. 7 (Palmer et al., 1991; Kay et al., 1992; Schleucher et al., 1994) . c 1 H, 1 H-COSY: homonuclear correlated spectroscopy. Magnitude experiment with z-gradient (Hurd, 1990; von Kienlin et al., 1991) . d Long-range 1 H, 13 C-COSY, HMBC experiment: heteronuclear correlated spectroscopy. Heteronuclear multiple bond correlation experiment with 1 H detection and z-gradient (Bax et al., 1986; Willker et al., 1993) .
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Iron Excretion. The potential contribution to chelation and elimination of iron of the primary hydroxylated metabolites M1 and M2 was assessed after intravenous administration of 10 mg/kg. Excretion of iron in bile and urine amounted to 62 g/day for M1 and 70 g/day for M2 and thus was substantially lower than that achieved with deferasirox (395 g/day).
Disposition in Mrp2-Deficient TR ؊ Rats. The role of the anion transporter Mrp2 in the disposition of deferasirox and its metabolites was investigated in TR Ϫ rats. This rat strain is deficient in the membrane transporter Mrp2 that catalyzes the hepatobiliary transport of conjugated bilirubin, glutathione conjugates, and other organic anions including drugs and drug conjugates (Dietrich et al., 2001; Kim et al., 2003; Chan et al., 2004; Borst et al., 2006) . On intravenous administration of 10 mg/kg [ 14 C]deferasirox, pharmacokinetics and disposition in the TR Ϫ rats differed markedly from those in HanoverWistar rats:
• The plasma concentrations of total radioactivity were far higher in TR Ϫ rats and decreased with a longer half-life (approximately 2 h, versus 0.7 h) (Fig. 2a) . The slower elimination of deferasirox-related radiolabeled material in TR Ϫ rats led to a 5-fold higher systemic exposure to 14 C components in TR Ϫ rats than in Hanover-Wistar rats. This indicated slower elimination processes with increased formation of metabolites.
• The biliary excretion of 14 C radioactivity was reduced in TR Ϫ rats to 43% of the dose (versus 69% in Hanover-Wistar rats) (Table 3) . On the other hand, excretion of 14 C radioactivity in urine was enhanced in TR Ϫ rats to 41% of the dose (versus approximately 8%) (Table 3 ).
• The metabolite patterns in plasma, bile, feces, and urine of TR Ϫ rats (Fig. 4 , e-h) showed much larger dose proportions in the form of metabolites. However, different types of metabolites were formed in the TR Ϫ rats: in the bile of Wistar rats, the main metabolite M3 (acyl glucuronide) accounted for 27% of the dose (Table 2 ; Fig. 4b ), whereas only a marginal amount of M3 was found in the bile of TR Ϫ rats (Fig. 4f) . On the other hand, a different glucuronide (M9) and particularly several sulfate conjugates (M7, M8, M9, M12, M13) were the major or even the predominant metabolites formed. The latter metabolites were excreted with both urine and bile (Table 3 ).
• Unchanged deferasirox accounted for a smaller radioactivity proportion in plasma, bile, feces, and urine (Fig. 4 , e-h), consistent with an increased extent of metabolism.
Discussion
An essential requirement for an efficacious p.o. iron-chelating drug is an optimal gastrointestinal absorption after p.o. dosing. The studies reported here show that deferasirox administered p.o. to rats is absorbed to at least 75%, and the bioavailability was 26%. The difference between absorption and bioavailability after p.o. administration was probably because of hepatic first-pass elimination via bile.
After intravenous and p.o. administration, deferasirox was present in the blood circulation mainly in the unchanged form and as its iron complex, Fe(deferasirox) 2 . Deferasirox was 99.2% bound to plasma proteins. The iron complex had a smaller distribution volume than deferasirox, and the unbound fraction of the iron complex (0.3%) was smaller compared with deferasirox (Weiss et al., 2006) .
The volume of distribution of deferasirox was moderate. It was distributed throughout the body to a limited extent and for a short period of time, except in the kidney and liver. The liver is the key organ for elimination of deferasirox and its iron complex. In the liver, deferasirox binds iron, forming the Fe(deferasirox) 2 complex. The observed distribution pattern was typical for an organic acid compound, which is present as an anion at physiological pH. Deferasirox and the iron complex were eliminated rapidly from blood and the liver, largely via bile. Substantial concentrations of iron in bile and feces showed the intended elimination of iron caused by deferasirox (Hershko et al., 2001; Nick et al., 2003) .
Systemic elimination of deferasirox in the rat was mainly, but not exclusively, a result of metabolism. The major metabolism pathways in the rat were direct glucuronidation that produced metabolites M3 and M6; hydroxylations at the phenol rings that resulted in metabolites M1, M2, M4, and M5; and conjugation of the hydroxylated metabolites with glucuronic acid and/or sulfate. It should be noted that at physiological pH, deferasirox and all its metabolites are mono-or di-anions. Likewise, the iron complex of deferasirox carries three negative charges. This suggests a major role for anion transport systems involved mainly in the hepatic uptake and hepatobiliary elimination process of deferasirox, as further discussed below. Likewise, the oxidative processes have been observed in in vitro studies of human hepatic microsomes. They are catalyzed mainly by human CYP1A1 and CYP1A2 enzymes, resulting in metabolites M1 and M2, and to a lower degree by the human CYP2D6, producing metabolite M4 (H. J. Einolf, R. Peter, L. Schofield, J. Chin, M. Shapiro, and H. Yin, unpublished data) (Novartis).
The main metabolite in the bile, M3, may retain the capability to form an iron complex because glucuronic acid is attached to the molecule at a position distant from the complex-forming moiety. The metabolites M1 and M2 also retain the structural requirements to chelate iron. However, after intravenous administration of M1 and M2, comparatively low amounts of iron were eliminated. Therefore, after p.o. dosing of deferasirox the metabolites M1 and M2 will minimally contribute to the therapeutic effect.
In the present study, unambiguous elucidation of the chemical structures of all the relevant deferasirox metabolites formed in the rat was achieved. A key step toward this goal was the unambiguous identification of the C-3 and C-5 atoms in the 13 C NMR spectra of the triazole ring and subsequent assignment of all the 13 C and 1 H signals of the phenol rings.
The disproportional increase of systemic exposure at the high-dose level suggested that transport process(es), rather than biotransformation processes, are saturated. Excretion of deferasirox and metabolites occurred largely within 24 h and was complete within 7 days. Residual traces of radioactivity were detected in the skin, kidney, and liver. The biliary/fecal route of excretion was predominant. Furthermore, deferasirox was marginally secreted with milk (3% of dose) and subsequently absorbed by the suckling pups. In these pups, the maximal concentration in highest exposed tissues (kidney cortex and liver) was approximately 8 times lower than in respective tissues of male rats serving as surrogate for dams. In the placental transfer study, the fetuses were also marginally exposed to the compound and/or its metabolites. From this finding it can be derived that human fetuses and infants will not be significantly exposed to deferasirox and/or its metabolites after p.o. administration to the mother.
The large proportion of dose that was excreted with the feces after p.o. administration was predominantly the unchanged parent drug. This was because of 1) biliary elimination of deferasirox; 2) biliary elimination and intestinal hydrolysis of the glucuronide M3; 3) biliary elimination and dissociation of the Fe(deferasirox) 2 complex in the gut; and 4) incomplete intestinal absorption. The presence of large amounts of deferasirox in the intestine explains the observed reabsorption and enterohepatic recirculation and the corresponding pharmacokinetics. It is important to note that p.o. administered deferasirox did not increase intestinal uptake of iron (Nick et al., 2000) . This finding was supported by in vitro data obtained with Caco-2 cells where transport of deferasirox but not the deferasirox-iron complex Otherwise, the fecal metabolite pattern was the same as phase I metabolites observed with liver microsomes in vitro. They were eliminated by conjugates with the bile and were released from the conjugates in the gut by chemical and/or microbial hydrolysis. In conclusion, deferasirox showed biopharmaceutical and metabolic properties that seem to be favorable for the intended p.o. therapeutic purpose of chelation and elimination of iron from the body.
Pharmacokinetics, metabolism, and elimination of deferasirox differed strongly between Hanover-Wistar and TR Ϫ rats, the latter being deficient in the anion transporter Mrp2. The observations in the TR Ϫ rats confirm that the expression level of the transport protein Mrp2 has a marked impact on excretion and metabolism of deferasirox. The acyl glucuronide M3 is the major metabolite in normal rats, but only marginal amounts of M3 were excreted in TR Ϫ rats. It could be hypothesized that this finding might be because of a deficiency of this strain in the specific glucuronyl transferase required. However, there are no data supporting this. It is far more likely that the acyl glucuronide M3 was formed in TR Ϫ rats and that it is a good substrate of Mrp2. Although in the TR Ϫ rats, any formed M3 could not be eliminated with the bile. In this situation M3 could be subject to esterase hydrolysis, liberating deferasirox, so that overall the formation of M3 seemed suppressed. Therefore, metabolism and elimination were deviated to alternative processes, which led to stable terminal metabolites, i.e., O-sulfates and O-glucuronic acid conjugates of primary hydroxylated metabolites including M1 and M2. The conjugates were finally excreted via alternative transport systems and routes, with a marked shift toward the renal route. The major compensating metabolic process seems to be O-conjugation with sulfate.
Apart from the main metabolite M3, unchanged deferasirox also was excreted to a lower extent in TR Ϫ rats. This observation indicates that the unchanged deferasirox is also a substrate of Mrp2.
From all the results described in this article, an overall picture emerges for the disposition of p.o. administered deferasirox in rats, as described schematically in Fig. 9 . This includes the following processes:
• The anion deferasirox can be eliminated from the liver into the bile.
This process seems to be catalyzed, at least partly, by Mrp2.
• A major elimination process is the biotransformation of deferasirox to the anionic acyl glucuronide M3. M3 is a substrate of Mrp2 and is transported efficiently to the bile. • In the gut, the acyl glucuronide M3 is unstable and will undergo hydrolysis to deferasirox, which will lead to some enterohepatic recirculation. The hydrolysis is probably caused by microbial glucuronidases, although spontaneous hydrolysis cannot be excluded. The lower proportion of unchanged deferasirox seen in plasma of TR Ϫ rats may be partly because of diminished enterohepatic circulation resulting from reduced biliary excretion of both deferasirox and M3.
• Additional metabolites formed are the primary hydroxylated derivatives M1, M2, and M4. These compounds undergo O-conjugation with sulfate and glucuronic acid. The resulting anionic O-conjugates (M7, M8, M9, M12, and M13) are excreted both with bile and urine.
• If direct biliary elimination of deferasirox, and particularly if the key pathway to M3 is "suppressed" because of deficiency in Mrp2, elimination by metabolism and hepatobiliary transport is slowed down, and the metabolism is shifted to other processes. Thus, the basically minor metabolic processes compensate for the deficient key processes.
• The anionic O-conjugates formed as terminal metabolites can be eliminated to the bile; although to a similar degree, they are excreted by the alternative renal route. The latter implies that they are eliminated from the liver via basolateral transporter to the blood, and subsequently from the kidney to the urine. This results in an overall shift in the excretion routes and in the patterns of metabolites in the excreta.
• The transporter eliminating deferasirox and metabolites to the sinusoidal blood is unknown. However, a likely transport system is Mrp3. This carrier is localized at the basolateral membrane, is involved in the excretion of various organic anions from liver, and is known to be up-regulated in case of mrp2 deficiency (König et al., 1999) . FIG. 9 . Proposed scheme for the disposition of deferasirox after p.o. administration in normal rats and the role of Mrp2 therein. The substantial enterohepatic circulation is also included in this scheme.
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Overall, the herein reported studies have provided a comprehensive picture of the disposition of deferasirox in the rat and of the involved processes.
